Recent developments in advanced urothelial cancer

Current Opinion in Urology

Volumn 15, Issue 5, 2005, Pages 342-349

  Chee, Karen Giselle ^a   Cambio, Angelo ^a   Lara Jr , Primo N ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Chemotherapy; Epidermal growth factor receptor; Metastatic bladder cancer

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; BORTEZOMIB; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; FLUOROURACIL; GEFITINIB; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INTEGRIN; INTERFERON; LAPATINIB; METHOTREXATE; OXALIPLATIN; PACLITAXEL; PEMETREXED; PROTEIN BCL 2; PROTEIN P21; PROTEIN P53; THROMBOSPONDIN 1; TRASTUZUMAB; UNINDEXED DRUG; UVOMORULIN; VINBLASTINE;

BLADDER CANCER; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DNA MICROARRAY; DRUG TOLERABILITY; HUMAN; METASTASIS; NEPHROTOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; STOMATITIS; UROGENITAL TRACT TUMOR;

EID: 24144457800     PISSN: 09630643     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mou.0000176047.23089.c7     Document Type: Review

References (64)

1. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005; 55:10-30.
2. Hayne D, Arya M, Quinn MJ, et al. Current trends in bladder cancer in England and Wales. J Urol 2004; 172:1051-1055. This a case-based review of the diagnosed bladder carcinoma at one registry in the UK and the relationship between gender and survival.
3. Madeb R, Messing EM. Gender, racial and age differences in bladder cancer incidence and mortality. Urol Oncol 2004; 22:86-92. This a review of the current epidemiological studies evaluating the effects of gender, race, and age on the incidence and mortality of bladder cancer.
4. Saxman SB, Propert KJ, Einhorn LH, et al. Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 1997; 17:3068-3077.
5. Bellmunt J, Albiol S. New chemotherapy combinations for advanced bladder cancer. Curr Opin Urol 2001; 11:517-522.
6. Sternberg CN, Yahoda A, Scher HI, et al. Methorexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Cancer 1989; 64:2448-2458.
7. Von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000; 17:3068-3077.
8. Hoque MO, Lee CR, Cairns P, et al. Genome-wide genetic characterization of bladder cancer: a comparison of high-density single-nucleotide polymorphism arrays and PCR-based microsatellite analysis. Cancer Res 2003; 63:2216-2222.
9. Ornskov D, Nexo E, Sorensen BS. Real-time polymerase chain reaction is a sensitive and precise method for quantifying transcription from reporter plasmids. Scand J Clin Lab Invest 2004; 64:723-728.
10. Grossman HB, Messing E, Soloway M, et al. Detection of bladder cancer using a point-of-care proteomic assay. JAMA 2005; 293:810-816. This is a multicenter trial comparing the measurement of the urinary nuclear matrix protein, NMP22, in a proteomic test to urine cytology in detecting the presence of a malignancy. The authors concluded that this measuring of NMP22 will increase the accuracy in detecting bladder cancer when added to a cystoscopy.
11. Kim JK, Park SY, Ahn HJ, et al. Bladder cancer: analysis of multi-detector row helical CT enhancement pattern and accuracy in tumor detection and perivesical staging. Radiology 2004; 231:725-731. This is a small study evaluating the use of helical CT in tumor detection and perivesical staging in 20 patients.
12. Schöder H, Larson SM. Positron emission tomography for prostate, bladder, and renal cancer. Semin Nucl Med 2004; 34:274-292. This is a review of the use of PET scans in the staging and monitoring of genitourinary malignancies, including bladder cancer.
13. Carles J, Nogue M. Gemcitabine/carboplatin in advanced urothelial cancer. Semin Oncol 2001; 28(3 Suppl 10):19-24.
14. Shannon C, Crombie C, Brooks A, et al. Carboplatin and gemcitabine in metastatic transitional cell carcinoma of the urothelium: effective treatment of patients with poor prognostic features. Ann Oncol 2001; 12:947-952.
15. Hussain M, Vaishampayan U, Du W, et al. Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer. J Clin Oncol 2001; 19:2527-2533.
16. Dominguez-Escrig JL, Kelly JD, Neal DE, et al. Evaluation of the therapeutic potential of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in preclinical models of bladder cancer. Clin Cancer Res 2004; 10:4874-4884. This is a study evaluating the different doses of gefitinib in multiple bladder cancer cell lines in comparison to these multiple cell lines placed in mice. Gefitinib exhibited inhibitory effects in vitro which was not seen in vivo suggesting that the application of this tyrosine kinase inhibitor may need to be given discriminately.
17. Hussain M, Petrylak D, Dunn R, et al. Trastuzumab (T), paclitaxel (P), carboplatin (C), and gemcitabine (G) in advanced Her-2 positive urothelial carcinoma: results of a multi-center phase II NCI trial [abstract 4507]. Proc Am Soc Clin Oncol 2005; 23:379. This recent abstract demonstrates clinical activity of trastuzumab in selected patients and lends support for a phase III trial.
18. Esrig D, Elmajian D, Groshen S, et al. Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med 1994; 331:1259-1264.
19. Waldman T, Zhang Y, Dillehay L, et al. Cell-cycle arrest versus cell death in cancer therapy. Nat Med 1997; 3:1034-1036.
20. Stein JP, Ginsberg DA, Grossfeld GD, et al. Effect of p21 expression on tumor progression in bladder cancer. J Natl Cancer Inst 1998; 90:1072-1079.
21. O'Connor PM, Jackman J, Bae I, et al. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res 1997; 57:4285-4300.
22. Garcia del Muro X, Condom E, Vigues F, et al. p53 and p21 expression levels predict organ preservation and survival in invasive bladder carcinoma treated with a combined-modality approach. Cancer 2004; 100:1859-1867. This is a prospective study to establish the relationship of p52 and p21 expression to both disease-free survival and overall survival in patients with invasive bladder cancer.
23. Gontero P, Banisadr S, Frea B, et al. Metastasis markers in bladder cancer: a review of the literature and clinical considerations. Eur Urol 2004; 46:296-311. A review of the known markers involved in the metastatisation of bladder cancer and their known molecular activity is outlined here.
24. Theodorescu D, Sapinoso LM, Conaway MR, et al. Reduced expression of metastasis suppressor RhoGD12 is associated with decreased survival for patients with bladder cancer. Clin Cancer Res 2004; 10:3800-3806. The details of a study using tissue microarrays to evaluate the expression of RhoGD12, a metastasis suppressor gene and its potential role as a prognostic factor in patients with bladder cancer are included.
25. Theodoropoulos VE, Lazaris AC, Sofras F, et al. Hypoxia-inducible factor 1α expression correlates with angiogenesis and unfavorable prognosis in bladder cancer. Eur Urol 2004; 46:200-208. The expression of hypoxia-inducible factor 1 α is evaluated in 93 bladder carcinoma tissue samples in relation to time of disease recurrence and poor prognosis.
26. Hovey RM, Chu L, Balazs M, et al. Genetic alterations in primary bladder cancers and their metastases. Cancer Res 1998; 58:3555-3560.
27. Modlich O, Risack HB, Pitschke G, et al. Identifying superficial, muscle-invasive, and metastasizing transitional cell carcinoma of the bladder: use of cDNA array analysis of gene expression profiles. Clin Cancer Res 2004; 10:3410-3421. The use of filter-based cDNA assay in a set of known superficial and invasive bladder cancer lines revealed the presence of certain gene clusters associated with the two different cancer lines.
28. Bar-Haim E, Paz A, Machlenkin A, et al. MAGE-A8 overexpression in transitional cell carcinoma of the bladder: identification of two tumour-associated antigen peptides. Br J Cancer 2004; 91:398-407. DNA micro-array technology was used to detect MAGE-A8 gene expression in tumor cells. Further studies from this gene expression identified two tumor-associated antigen peptides.
29. Mallampati GK, Siegelman ES. MR imaging of the bladder. Magn Reson Imaging Clin N Am 2004; 12:545-555. This is a review of the use of MRI in detecting and staging bladder cancer.
30. Bachor R, Kotzerke J, Reske SN, Hautmann R. Lymph node staging of bladder neck carcinoma with positron emission tomography. Urologe 1999; 38:46-50.
31. Loehrer PJ Sr, Einhorn LH, Elson PJ, et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin, in patients with metastatic urothelial carcinoma: a Cooperative Group Study. J Clin Oncol 1992; 10:1066-1073.
32. Logothetis CJ, Dexeus FH, Finn L, et al. A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol 1990; 8:1050-1055.
33. Siefker-Radtke AO, Millikan RE, Tu SM, et al. Phase III trial of fluorouracil, interferon alfa-2b, and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in metastatic or unresectable urothelial cancer. J Clin Oncol 2002; 20:1361-1367.
34. Hussain SA, Stocken DD, Riley P, etal. A phase I/II study of gemcitabine and fractionated cisplatin in an outpatient setting using a 21-day schedule I patients with advanced and metastatic bladder cancer. Br J Cancer 2004; 91:844-849. This is a phase I/II study of gemcitabine and fractionated cisplatin given every 3 weeks is found to be active and well tolerated among 19 patients with decreased renal reserve.
35. Lippert CM, Meisel T, Becht E, et al. A new concept of continuous gemcitabine infusion: fixed-dose-rate gemcitabine plus platinum in metastatic transitional cancer - preliminary result of a phase I study [abstract 4641]. Proc Am Soc Clin Oncol 2004; 22:417. This is an abstract reporting the necessary dose reduction of gemcitabine in this phase I study due to significant hematologic toxicities.
36. Clark PE, Stindt D, Hal MC, et al. Phase II trial of gemcitabine, paclitaxel, and cisplatin in advanced transitional cell carcinoma [abstract 4610]. Proc Am Soc Clin Oncol 2004; 22:409. This abstract reported the triplet combination of chemotherapy having a relatively high response rate in this small group of patients.
37. Bellmunt J, Guillern V, Paz-Ares L, et al. Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. J Clin Oncol 2000; 18:3247-3255.
38. Linardou H, Aravantinos G, Efstathiou E, et al. Gemcitabine and carboplatin combination as first-line treatment in elderly patients and those unfit for cisplatin-based chemotherapy with advanced bladder carcinoma: phase II study of the Hellenic Cooperative Oncology Group. Urology 2004; 64:479-483. This phase II study of gemcitabine and carboplatin did show activity in this selected group of patients.
39. Carles J, Nogue M, Domenech M, et al. Carboplatin-gemcitabine treatment of patients with transitional cell carcinoma of the bladder and impaired renal function. Oncology 2000; 59:24-37.
40. Chen AC, Hovey E, Shelton G, et al. Phase I/II study of docetaxel (D), gemcitabine (G), carboplatin (C) in poor prognosis and previously treated patients (pts) with urothelial carcinoma (UTC) [abstract 4580]. Proc Am Soc Clin Oncol 2004; 22:401. Another triplet therapy is evaluated in this abstract with activity, even in patients who had received prior chemotherapy.
41. Chabine GY, Kattan JG, Farhat FS, et al. The weekly triplet: gemcitabine, carboplatin and paclitaxel as first line therapy for advanced urothelial cancer [abstract 4704]. Proc Am Soc Clin Oncol 2004; 22:432. This abstract reported comparable response rates to the previous triplet combina-tions listed above.
42. Hoshi S, Ohyama C, Ono K, et al. Gemcitabine plus carboplatin; and gemcitabine, docetaxel, and carboplatin combined chemotherapy regimens in patients with metastatic urothelial carcinoma previously treated with a platinum-based regimen: preliminary report. Int J Clin Oncol 2004; 9:125-129. This is a trial that attempts to compare a doublet chemotherapy with a triplet chemotherapy schedule with a suggestion that both combinations are active in previously treated patients.
43. Font A, Esteban E, Carles J, et al. Gemcitabine and oxaliplatin combination: a multicenter phase II trial in unfit patients with locally advanced or metastatic urothelial cancer [abstract 4544]. Proc Am Soc Clin Oncol 2004; 22:392. This abstract reported the results of a multicenter phase II trial suggesting that oxaliplatin may be an acceptable alternative to cisplatin when combined with gemcitabine in treating metastatic disease.
44. McCaffery JA, Hilton S, Mazumdar M, et al. Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma. J Clin Oncol 1997; 15:1853-1857.
45. Roth BJ, Dreicer R, Einhorn LH, et al. Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group. J Clin Oncol 1994; 15:317-329.
46. Boyer MJ, Gurney H, Rosenthal MA, et al. Randomised phase II study of gemcitabine (G) with either carboplatin (C) or docetaxel (D) in patients with locally advanced or metastatic transitional cell carcinoma (TCC) of the urothelium: preliminary results [abstract 1568]. Proc Am Soc Clin Oncol 2003; 22:390.
47. Ardavanis A, Tryfonopoulos D, Alexopoulus A, et al. Gemcitabine and docetaxel as first-line treatment for advanced urothelial carcinoma: a phase II study. Br J Cancer 2005; 92:645-650. This phase II trial reported equivalent response rates of a nonplatinum based doublet chemotherapy combination when compared to previous known response rates to MVAC therapy.
48. Srinivas S, Guardino AE. Gemcitabine and paclitaxel chemotherapy effective for good risk advanced urothelial malignancies [abstract 4675]. Proc Am Soc Clin Oncol 2004; 22:425. This abstract suggested that this nonplatinum doublet can be used in patients with good performance status and nonvisceral metastatic disease.
49. Lara PN Jr, Meyers FJ, Law LY, et al. Platinum-free combination chemotherapy in patients with advanced or metastatic transitional cell carcinoma: a phase I/II trial of gemcitabine, paclitaxel, and methotrexate. Cancer 2004; 100:82-88. This paper highlighted a possible triplet combination without the use of a platinum agent with comparable response rates.
50. Chow HG, Liu HS, Lee EIC, et al. Significance of urinary epidermal growth factor and its receptor expression in human bladder cancer. Anticancer Res 1997; 17:1293-1296.
51. Lipponen P, Eskelinen M. Expression of epidermal growth factor receptor in bladder cancer as related to established prognostic factors, oncoprotein (c-erbB-2, p52) expression and long-term prognosis. Br J Cancer 1994; 69:1120-1125.
52. Neal DE, Sharples L, Smith K, et al. The epidermal growth factor receptor and the prognosis of bladder cancer. Cancer 1990; 65:1619-1625.
53. Nutt JE, Lazarowicz HP, Mellon JK, et al. Gefitinib ('Iressa', ZD1839) inhibits the growth response of bladder tumour cell lines to epidermal growth factor and induces TIMP2. Br J Cancer 2004; 90:1979-1985. The study used gefitinib in two bladder tumour cell lines and confirmed the activity seen in other studies.
54. Petrylak D, Faulkner JR, Van Veldhuizen PJ, et al. Evaluation of ZD1839 for advanced transitional cell carcinoma (TCC) of the urothelium: a Southwest Oncology Group Trial [abstract 1619]. Proc Am Soc Clin Oncol 2003; 22:403.
55. Philips G, Halabi S, Sanford B, et al. Phase II trial of cisplatin (C), fixed-dose rate gemcitabine (G) and gefitinib for advanced transitional cell carcinoma (TCC) of the urothelial tract: preliminary results of CALGB 90102 [abstract 4540]. Proc Am Soc Clin Oncol 2004; 22:391. This abstract reported the early results of adding gefitinib to cisplatin/gemcitabine. While there was activity seen in a small number of patients, this study was halted temporarily secondary to significant toxicities. The study has been resumed with an adjustment made to the gemcitabine dose. The exact contribution of gefitinib to the chemotherapy doublet is not yet known.
56. Latif Z, Watters AD, Dunn I, et al. Her2/neu gene amplification and protein overexpression in G3pT2 transitional cell carcinoma of the bladder: a role for anti-HER2 therapy? Eur J Cancer 2004; 40:56-63. This article reported the discordance between Her2/neu gene amplification and protein overexpression.
57. Coogan CL, Extrada CR, Kapur S, et al. HER-2/neu protein overexpression and gene amplification in human transitional cell carcinoma of the bladder. Urology 2004; 63:786-790. This is a similar article to the previous one confirming the lack of Her2/neu gene amplification in the setting of positive protein overexpression.
58. Latif Z, Watters AD, Dunn I, et al. HER2/neu overexpression in the development of muscle-invasive transitional cell carcinoma of the bladder. Br J Cancer 2003; 89:1305-1309.
59. Machiels JP, Wulfing C, Richel DJ, et al. A single arm, multicenter, open-label phase II study of orally administered GW572016 as single-agent, second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract. Interim analysis [abstract 4615]. Proc Am Soc Clin Oncol 2004; 22:410. This abstract reported an activity using this dual inhibitor of ErbB1 and ErbB2 receptors as a single agent in patients with known metastatic disease suggesting the need for further trials.
60. Schaaf A, Sreedhar S, Langbein S, et al. Cytotoxicity of cisplatin in bladder cancer is significantly enhanced by application of bcl-2 antisense oligonucleotides. Urol Oncol 2004; 22:188-192. This study reported the use of a new class of compounds having activity when combined with a cytotoxic agent towards bladder cancer cell lines.
61. Muramaki M, Miyake H, Kara I, et al. Synergistic inhibition of tumor growth and metastasis by combined treatment with TNP-470 and gemcitabine in a human bladder cancer KOTCC-1 model. J Urol 2004; 172:1485-1489. This study evaluated the use of an angiogenesis inhibitor in combination with a cytotoxic agent in a bladder cancer cell line and reported synergistic activity with respect to inhibiting tumor growth.
62. Pauer LR, Olivares J, Cunningham C, et al. Phase I study of oral CI-994 in combination with carboplatin and paclitaxel in the treatment of patients with advanced solid tumors. Cancer Invest 2004; 22:886-896. This study used a novel, oral histone deacetylase inhibitor in combination with chemotherapeutic agents in patients with solid tumors. Of the two patients who achieved a complete response, one had advanced bladder cancer.
63. Bellmunt J, Hussain M, Dinney CP. Novel approaches with targeted therapies in bladder cancer: therapy of bladder cancer by blockade of the epidermal growth factor receptor family. Crit Rev Oncol Hematol 2003; 46:S85-S104.
64. Dreicer R, Manola J, Roth BJ, et al. Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium: a trial of the Eastern Cooperative Oncology Group. Cancer 2004; 100:1639-1645. This is the only phase III trial published recently comparing a doublet, carboplatin and paclitaxel, to MVAC. The study failed to reach its accrual goal but did report a statistically significant worse toxicity profile in the patients receiving MVAC therapy. Unfortunately, no further conclusions with respect to efficacy can be drawn given the limitations of the studies leaving the use of carboplatin and paclitaxel in patients with metastatic bladder cancer as an unanswered question.